Latest Period
Q2 2026
Security Snapshot
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS) Institutional Ownership
CUSIP: 00461U105
13F Institutional Holders and Ownership History from Q4 2015 to Q2 2026
Institutions Reporting
148
Shares (Excl. Options)
119,140,560
Price
$5.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- ACRS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 119,140,560
- Total 13F value
- $630,033,549
- Portfolio coverage rank
- 0.01%
- Share change
- +9,921,232
- Value change
- +$55,595,022
- Number of holders
- 148
- Shares outstanding
- 139,813,473
- SEC-reported price per share
- $5.37
- Insider filing price
- $5.37
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 00461U105.
- 148 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 135 to 148 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $409,401,104 to $630,033,549.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 148 institutions filings for Q2 2026.
Security key
00461U105
Latest holder period
Q2 2026
13F holders
148
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
ACRS full holder history
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Aclaris Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00461U105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ACRS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | -17% | $52,312,500 | -$1,125,000 | 13,950,000 | -2.1% | BML Investment Partners, L.P. | 23 Apr 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.1% | +47% | $71,503,406 | +$28,641,324 | 12,723,026 | +67% | RA Capital Management, L.P. | 30 Jun 2026 |
| Bonita Biotech (HK) Ltd | 9.4% | $33,944,003 | 11,281,950 | Biosion, Inc. | 09 Dec 2025 | |||
| Deep Track Capital, LP | 7% | $33,735,450 | 9,345,000 | Deep Track Capital, LP | 09 Mar 2026 | |||
| BlackRock, Inc. | 6.2% | +22% | $20,164,873 | +$3,698,306 | 6,700,629 | +22% | BlackRock, Inc. | 31 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 4.3% | $22,373,888 | 5,966,370 | Vivo Opportunity Fund Holdings, L.P. | 31 Mar 2026 | |||
| Adage Capital Management, L.P. | 4.9% | -34% | $10,028,474 | -$5,554,080 | 5,278,144 | -36% | Adage Capital Management, L.P. | 30 Sep 2025 |
| Rock Springs Capital Management LP | 4.7% | $7,720,853 | 5,046,309 | Rock Springs Capital Management LP | 31 Mar 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 3.5% | -32% | $5,449,080 | -$2,422,176 | 3,837,380 | -31% | Millennium Management LLC | 30 Jun 2025 |
As of 30 Jun 2026, 148 institutional investors reported holding 119,140,560 shares of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value per share (ACRS). This represents 85% of the company’s total 139,813,473 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
73%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.1% | 12,723,026 | +87% | 0.58% | $67,304,808 |
| BML Capital Management, LLC | 8.6% | 11,975,000 | -16% | 36% | $63,347,750 |
| BlackRock, Inc. | 7.2% | 10,037,008 | +36% | 0% | $53,095,772 |
| Deep Track Capital, LP | 6.7% | 9,345,000 | 0% | 0.73% | $49,435,050 |
| Vivo Capital, LLC | 4.8% | 6,694,637 | +0.42% | 3.2% | $35,414,630 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 5,817,866 | +13% | 0% | $30,776,511 |
| Frazier Life Sciences Management, L.P. | 3.5% | 4,925,374 | 0% | 0.57% | $26,055,228 |
| Rock Springs Capital Management LP | 3.1% | 4,330,532 | -3.2% | 1.1% | $22,908,514 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.9% | 4,071,000 | +5.2% | 0.03% | $21,535,590 |
| Decheng Capital LLC | 2.9% | 4,041,736 | 0% | 2.9% | $21,380,783 |
| STATE STREET CORP | 2.3% | 3,255,340 | +62% | 0% | $17,220,749 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 3,190,058 | +32% | 0% | $16,879,468 |
| BRAIDWELL LP | 1.5% | 2,142,348 | +26% | 0.42% | $11,333,021 |
| Balyasny Asset Management L.P. | 1.4% | 2,023,470 | -40% | 0.02% | $10,704,156 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.4% | 1,946,482 | 1.1% | $10,296,890 | |
| Kalehua Capital Management LLC | 1.3% | 1,832,365 | 0% | 5.6% | $9,693,211 |
| CITADEL ADVISORS LLC | 1.3% | 1,762,081 | -22% | 0.01% | $9,321,408 |
| Jones Hill Capital LP | 1.3% | 1,759,492 | 2% | $9,307,713 | |
| ACADIAN ASSET MANAGEMENT LLC | 1.2% | 1,641,472 | +6.6% | 0.01% | $8,677,000 |
| Palo Alto Investors LP | 1.2% | 1,613,430 | 0% | 1.2% | $8,535,045 |
| Woodline Partners LP | 1.2% | 1,611,054 | +8.4% | 0.03% | $8,522,476 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1% | 1,465,735 | -11% | 0% | $7,753,738 |
| PANAGORA ASSET MANAGEMENT INC | 0.97% | 1,356,152 | +170% | 0.02% | $7,174,044 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.87% | 1,209,886 | -15% | 0.01% | $6,400,297 |
| MPM BIOIMPACT LLC | 0.75% | 1,042,467 | +166% | 0.34% | $5,514,650 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
43
Latest
Q2 2026
Rows shown
1-25 of 43
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 119,140,560 | $630,033,549 | +$55,595,022 | $5.29 | 148 |
| 2026 Q1 | 109,211,572 | $409,401,104 | +$98,847,452 | $3.75 | 135 |
| 2025 Q4 | 83,739,024 | $252,051,598 | -$10,906,407 | $3.01 | 122 |
| 2025 Q3 | 85,675,311 | $162,782,120 | -$11,317,612 | $1.90 | 103 |
| 2025 Q2 | 91,862,480 | $130,443,350 | -$2,093,251 | $1.42 | 95 |
| 2025 Q1 | 92,164,636 | $141,009,418 | +$2,108,864 | $1.53 | 106 |
| 2024 Q4 | 87,478,919 | $216,988,373 | +$93,728,957 | $2.48 | 97 |
| 2024 Q3 | 50,891,008 | $58,523,068 | -$1,742,222 | $1.15 | 76 |
| 2024 Q2 | 52,848,132 | $58,129,308 | -$1,619,597 | $1.10 | 93 |
| 2024 Q1 | 54,386,842 | $67,436,941 | -$3,788,067 | $1.24 | 93 |
| 2023 Q4 | 58,449,543 | $61,369,526 | -$207,123,774 | $1.05 | 102 |
| 2023 Q3 | 70,071,814 | $479,974,125 | -$28,113,579 | $6.85 | 137 |
| 2023 Q2 | 71,014,841 | $736,442,996 | +$5,835,766 | $10.37 | 131 |
| 2023 Q1 | 71,610,627 | $579,302,266 | +$19,605,105 | $8.09 | 148 |
| 2022 Q4 | 65,900,596 | $1,037,946,141 | -$2,542,115 | $15.75 | 126 |
| 2022 Q3 | 63,675,444 | $1,002,225,041 | +$5,530,098 | $15.74 | 124 |
| 2022 Q2 | 63,269,555 | $883,318,693 | +$55,162,166 | $13.96 | 112 |
| 2022 Q1 | 59,295,213 | $1,021,908,185 | +$59,352,437 | $17.24 | 107 |
| 2021 Q4 | 56,045,310 | $814,890,981 | -$39,784,690 | $14.54 | 133 |
| 2021 Q3 | 56,785,960 | $1,022,155,424 | +$15,328,009 | $18.00 | 126 |
| 2021 Q2 | 56,004,936 | $983,410,407 | +$20,628,850 | $17.56 | 128 |
| 2021 Q1 | 45,417,666 | $1,298,594,000 | +$509,363,836 | $25.20 | 95 |
| 2020 Q4 | 31,934,018 | $206,591,000 | +$27,717,112 | $6.47 | 79 |
| 2020 Q3 | 25,553,008 | $65,673,000 | -$3,889,513 | $2.57 | 52 |
| 2020 Q2 | 28,456,883 | $46,099,261 | -$5,512,533 | $1.62 | 56 |